New osteoarthritis drug candidate APPA-1 passes first safety check in small trial
NCT ID NCT07429565
First seen Mar 12, 2026 · Last updated May 26, 2026 · Updated 14 times
Summary
This early-phase study tested APPA-1, a combination of two natural compounds, in 40 healthy volunteers and people with osteoarthritis. The main goal was to check safety and how the body processes the drug. Researchers also looked at whether food or gender affects drug levels. This is a first step toward finding a new treatment for osteoarthritis pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, L7 8XP, United Kingdom
-
University of Liverpool
Liverpool, L69 7ZB, United Kingdom
Conditions
Explore the condition pages connected to this study.